Home › Encyclopedia › ARA-290: Research Status and Clinical Trial Data
Research / Unapproved

ARA-290: Research Status and Clinical Trial Data

Molecular formulaC51H84N16O21
Molecular weight1257.3 g/mol
Registered trials4
PubChem CID91810664

What ARA-290 Is

ARA-290 is a synthetic peptide with the molecular formula C51H84N16O21 and a molecular weight of approximately 1,257.3 g/mol (PubChem CID 91810664). It has no FDA-approved label and is classified as an investigational compound under research study. No brand name, approved indication, or established mechanism-of-action statement exists in regulatory labeling for this substance.

Clinical Trial Footprint

Four trials involving ARA-290 are registered. Available records show studies spanning early and mid-stage phases rather than large confirmatory trials.

A phase 2 trial, "The Use of ARA290 for the Treatment of Diabetic Macular Oedema" (NCT06626971), was terminated. A combined phase 1/phase 2 study, "Cognitive and Neural Effects of ARA290" (NCT02070783), reached completed status. Another phase 2 trial, "Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis" (NCT02039687), was also completed. These records describe trial status only and do not establish that the compound is safe or effective for any use.

FAQ

Is ARA-290 FDA approved?
No. ARA-290 has no FDA-approved label, brand name, or approved indication. It is studied only in a research and clinical trial context.
What is ARA-290 made of?
ARA-290 is a synthetic peptide with the molecular formula C51H84N16O21 and a molecular weight of about 1,257.3 g/mol, identified in PubChem under CID 91810664.
How many clinical trials have studied ARA-290?
Four registered trials involve ARA-290, including studies in diabetic macular oedema, cognitive and neural effects, and corneal nerve fiber density in sarcoidosis. One of these trials was terminated while two others reached completed status.
Does the available data show ARA-290 works for any condition?
No. The clinical trial records describe study phases and status only, not outcomes or efficacy findings. No approved indication or confirmed benefit has been established.
Are there reported side effects for ARA-290?
No adverse event report data is currently available for this compound in the dataset reviewed.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-11-07